{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:50:04Z","timestamp":1778028604204,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00702-019-02029-5","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T16:02:17Z","timestamp":1560614537000},"page":"1337-1340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use"],"prefix":"10.1007","volume":"126","author":[{"given":"Dirk","family":"Dressler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Kollewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilmann H. C.","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Gade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sikorra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Bigalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"2029_CR1","first-page":"580","volume":"142","author":"J Demarchi","year":"1958","unstructured":"Demarchi J, Mourgues C, Orio J, Prevot AR (1958) Existence of type D botulism in man. Bulletin de l\u2019Academie Nationale de Medecine 142:580\u2013582","journal-title":"Bulletin de l\u2019Academie Nationale de Medecine"},{"key":"2029_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000067023","volume":"49","author":"D Dressler","year":"2003","unstructured":"Dressler D, Benecke R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49:34\u201338","journal-title":"Eur Neurol"},{"key":"2029_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000081463","volume":"52","author":"D Dressler","year":"2004","unstructured":"Dressler D, Bigalke H (2004) Antibody-induced failure of botulinum toxin type B therapy in de novo patients. Eur Neurol 52:132\u2013135","journal-title":"Eur Neurol"},{"key":"2029_CR4","volume-title":"Manual of botulinum toxin therapy","author":"D Dressler","year":"2009","unstructured":"Dressler D, Bigalke H (2009) Pharmacology of botulinum toxin drugs. In: Truong D, Dressler D, Hallett M (eds) Manual of botulinum toxin therapy. Cambridge University Press, Cambridge"},{"key":"2029_CR5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s004150070132","volume":"247","author":"D Dressler","year":"2000","unstructured":"Dressler D, Rothwell JC, Bigalke H (2000) The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 247:630\u2013632","journal-title":"J Neurol"},{"key":"2029_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, Benecke R, Bigalke H (2003) Botulinum toxin type B (NeuroBloc\u00ae) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 250:967\u2013969","journal-title":"J Neurol"},{"key":"2029_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0304-3940(97)13448-6","volume":"224","author":"R Eleopra","year":"1997","unstructured":"Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D (1997) Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 224:91\u201394","journal-title":"Neurosci Lett"},{"key":"2029_CR9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.clinph.2012.11.004","volume":"124","author":"R Eleopra","year":"2013","unstructured":"Eleopra R, Montecucco C, Devigili G, Lettieri C, Rinaldo S, Verriello L, Pirazzini M, Caccin P, Rossetto O (2013) Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study. Clin Neurophysiol 124:999\u20131004","journal-title":"Clin Neurophysiol"},{"key":"2029_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/mds.870120116","volume":"12","author":"KR Kessler","year":"1997","unstructured":"Kessler KR, Benecke R (1997) The EBD test\u2014a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12:95\u201399","journal-title":"Mov Disord"},{"key":"2029_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/BF01652699","volume":"101","author":"V Minor","year":"1928","unstructured":"Minor V (1928) Ein neues Verfahren zu der klinischen Untersuchung der Schweissabsonderung. Dtsch Z Nervenheilkd 101:302\u2013307","journal-title":"Dtsch Z Nervenheilkd"},{"issue":"8728","key":"2029_CR12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/0140-6736(90)93157-K","volume":"336","author":"K Oguma","year":"1990","unstructured":"Oguma K, Yokota K, Hayashi S, Takeshi K, Kumagai M, Itoh N, Tachi N, Chiba S (1990) Infant botulism due to Clostridium botulinum type C toxin. Lancet 336(8728):1449\u20131450","journal-title":"Lancet"},{"key":"2029_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.toxicon.2015.04.015","volume":"101","author":"S Pellett","year":"2015","unstructured":"Pellett S, Tepp WH, Scherf JM, Pier CL, Johnson EA (2015) Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon 101:63\u201369","journal-title":"Toxicon"},{"key":"2029_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","volume":"44","author":"LL Simpson","year":"2004","unstructured":"Simpson LL (2004) Identification of the major steps in botulinum toxin action. Ann Rev Pharmacol Toxicol 44:167\u2013193","journal-title":"Ann Rev Pharmacol Toxicol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02029-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-019-02029-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-019-02029-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T23:14:27Z","timestamp":1592090067000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-019-02029-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1007\/s00702-019-02029-5","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]},"assertion":[{"value":"5 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. KK received travel grants and honoraria for lectures from Allergan, Biogen, Ipsen and Merz. TK used to be member of the advisory board of Allergan (04\/12-09\/14). He has filed a patent on the use of botulinum toxin in the treatment of personality disorders. He received honoraria for talks from Allergan, Lilly, Lundbeck, Novartis, Otsuka, Schwabe, Servier and Trommsdorf for talks and advisory board activities. NG has no conflicts of interest. SS has no conflicts of interest. HB has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}